Newsletters and Deep Dive digital magazine
Beijing-based pharma, BeiGene’s
BeiGene’s plans for an early approval for BTK inhibitor zanubrutinib in the US and to start challenging Janssen/AbbVie’s blockbuster Imbruvica have suffered a setback.
Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
An inside guide to unlocking clinical research in the UK